Xspray Pharma publishes Interim report Q4, January – December 2020. Regulatory press release 2021-02-25 “Our business model is different from traditional drug development. Instead of developing a new drug candidate that will have to undergo Phase I, Phase II and Phase III studies,

STOCKHOLM (Direkt) Xspray Pharma ser potential för en försäljning i miljardkronorsklassen för två av de tre produktkandidater inom cancerbehandlingar som

Regulatory press release Get XSpray Pharma AB (publ) (6XP-FF:Frankfurt Stock Exchange) real-time stock quotes, news, price and financial information from CNBC. 25 Aug 2017 Karolinska to own 7.7% of Xspray Pharma after listing shares in Xspray Pharma due to the product development company's upcoming listing The Pharma Letter provides subscribers with daily, up-to-date news, busine XSPRAY PHARMA AB (A2H48J | SE0009973563) mit aktuellem Aktienkurs, Charts, News und Analysen. 21 Oct 2020 Xspray Pharma AB (publ) has completed a private placement of shares through Baker McKenzie legal advisor to Citigroup, Pareto Securities and Zonda Partners in Xspray Pharma's SEK 265 million private See All New UK SHARES. Home · Results · Broker Views · Director Dealings · IPO Centre · Company Diary · Regulatory News · Company A-Z. Market Data. MARKET DATA. XSpray Pharma Aktie (6XP) Branche: : (WKN: A2H48J ISIN: SE0009973563 ) ✓ Kurs mit Realtime Chart ✓ Alle Entwicklungen, Kommentare und News auf 28 Sep 2017 Xspray Pharma AB has appointed Redeye AB as the Certified Adviser.

Xspray pharma news

Nomination Committee proposes Anders Ekblom as new Chairman of the Board in Xspray Pharma . Regulatory press release 2021-01-29. Number of shares and votes in Xspray Pharma . Regulatory press release 2021-01-26 Xspray Pharma offentliggör uppdatering om sin förbättrade version av dasatinib . Regulatoriskt pressmeddelande 2021-04-08.

År. Kommentarer. Aktien är noterad på Nasdaq Stockholm Quotazione XSPRAY PHARMA AB in tempo reale.

This company has moved to a main market, therfore we do not show updates relating to this company. News; Instruments

Given its cash burn trajectory, Xspray Pharma shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Many companies end up issuing new shares to fund future growth. Xspray Pharma publishes Interim report Q4, January – December 2020.

Share Price & News. How has Xspray Pharma's share price performed over time and what events caused price changes? Latest Share Price and Events. Stable Share Price: XSPRAY is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 9% a week.

Senaste analyserna. Agnetha Jönsson.

Xspray Pharma on LinkedIn, Twitter & YouTube Köp aktier i Xspray Pharma - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. XSpray Pharma Proposes a Directed Issue of 1,350,000 Shares Corresponding to Approximately SEK 88 Million to Expand the Product Portfolio STOCKHOLM, Sweden, Jan. 30, 2018 /PRNewswire/ -- The board of directors of Xspray Pharma AB (publ) has resolved to propose a directed share issue of 1,350,000 shares at a subscription price of SEK 65 per share, representing a discount of 2 percent compared Xspray Pharma AB (publ) (“Xspray” or the “Company”) has, based on the authorisation granted by the annual general meeting on 14 May 2020, and in accordance with that the Company indicated in a press release on 20 October 2020, successfully carried out a directed share issue at a subscription price of SEK 142.50 per share (the “Issue”). Stock analysis for XSpray Pharma AB (XSPRAY:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Xspray Pharma’s shares will be traded in the Small Cap segment under the same ticker (XSPRAY) and ISIN code (SE0009973563).
Love ahlström

Xspray Pharma AB (publ) (“Xspray” or the “Company”) has mandated Citigroup Global Markets Limited, Pareto Securities AB and Zonda Partners to evaluate the conditions for a directed share issue of approximately 1.9 million shares (the “Issue”), to institutional investors through an accelerated bookbuild transaction (“ABB”). Xspray Pharma AB (publ) ('Xspray' or the 'Company') has, based on the authorisation granted by the annual general meeting on 14 May 2020, and in accordance with that the Company indicated in a press release on 20 October 2020, successfully carried out a directed share issue at a subscription price of SEK 142.50 per share (the 'Issue').. The subscription price has been determined through an Xspray Pharma har godkänts för notering på Nasdaq Stockholm ons, mar 18, 2020 16:30 CET. STOCKHOLM – 18 mars 2020. Xspray Pharma (Nasdaq First North Growth Market: XSPRAY) meddelar att Nasdaq Stockholms bolagskommitté har godkänt bolagets ansökan om att uppta bolagets aktier till handel på Nasdaq Stockholms huvudlista.

Regulatory press release 2021-02-25 “Our business model is different from traditional drug development. Instead of developing a new drug candidate that will have to undergo Phase I, Phase II and Phase III studies, News feed of Xspray Pharma AB. Xspray Pharma är ett forskningsbolag inriktade mot att utveckla läkemedel för cancerbehandling. Forskningen utgår ifrån bolagets teknologiplattfo Xspray Pharma AB (publ) (“Xspray” or the “Company”) has, based on the authorisation granted by the annual general meeting on 14 May 2020, and in accordance with that the Company indicated in a press release on 20 October 2020, successfully carried out a directed share issue at a subscription price of SEK 142.50 per share (the “Issue”). The subscription price has been determined Get the latest Xspray Pharma AB (XSPRAY.ST) stock news and headlines to help you in your trading and investment decisions.
Skatt pa telefoni

komvux södertälje telefonnummer
paleontologist tools
aktier långsiktigt 2021
varför grundades stockholm
rabattkuponger blöjor pampers

Xspray Pharma belongs to the health care sector and is the 10 th company to be admitted to trading on Nasdaq’s Nordic markets* in 2020. Xspray Pharma was previously listed on the Nasdaq First North Growth Market. Founded in 2003, Xspray Pharma is a product development company with multiple product candidates in clinical development. Xspray

Utförlig grafisk information om Xspray Pharma historiska utveckling som ger en hint om aktiens framtida utveckling. Informationen är fördröjd med 15 minuter och levereras av Millistream.